1. Comparison of long‐term safety of fixed‐dose combinations azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide. Issue 9 (6th July 2017) Authors: Neutel, Joel M.; Cushman, William C.; Lloyd, Eric; Barger, Bruce; Handley, Alison Journal: Journal of clinical hypertension Issue: Volume 19:Issue 9(2017) Page Start: 874 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Evaluation of the angiotensin II receptor blocker azilsartan medoxomil in African‐American patients with hypertension. Issue 7 (11th May 2017) Authors: Johnson, Wallace; White, William B.; Sica, Domenic; Bakris, George L.; Weber, Michael A.; Handley, Alison; Perez, Alfonso; Cao, Charlie; Kupfer, Stuart; Saunders, Elijah B. Journal: Journal of clinical hypertension Issue: Volume 19:Issue 7(2017) Page Start: 695 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Safety and tolerability of azilsartan medoxomil in subjects with essential hypertension: a one-year, phase 3, open-label study. (17th February 2016) Authors: Handley, Alison; Lloyd, Eric; Roberts, Andrew; Barger, Bruce Journal: Clinical and experimental hypertension Issue: Volume 38:Number 2(2016) Page Start: 180 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Safety, Tolerability, and Efficacy of Azilsartan Medoxomil With or Without Chlorthalidone During and After 8 Months of Treatment for Hypertension. Issue 3 (24th January 2015) Authors: Kipnes, Mark S.; Handley, Alison; Lloyd, Eric; Barger, Bruce; Roberts, Andrew Journal: Journal of clinical hypertension Issue: Volume 17:Issue 3(2015:Mar.) Page Start: 183 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗